From Wikipedia, the free encyclopedia
Lucatumumab is a human monoclonal antibody[1] being investigated for the treatment of various types of cancer like multiple myeloma,[2] non-Hodgkin's or Hodgkin's lymphoma.[3]
This drug was developed by Novartis Pharmaceuticals Corp.
[edit] References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ^ ClinicalTrials.gov NCT00231166
- ^ ClinicalTrials.gov NCT00670592
|
Human monoclonal antibodies ("-u-") |
|
| "-limu-" (immune system) |
|
|
| "-kinu-" (interleukin as target) |
|
|
| "-tumu-" (cancer immunotherapy) |
Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Necitumumab, Ofatumumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab
|
|
| "-osu-" (bone) |
|
|
| "-mulu-" (musculoskeletal) |
|
|
| "-fungu-" (fungal) |
|
|
| "-viru-" (viral) |
|
|
| "-bacu-" (bacterial) |
|
|
| "-ciru-" (cardiovascular) |
|
|
| "-neru-" (neurologic) |
|
|
| #WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III |
|
